Investor Alert: Entheon Biomedical - Treating Addiction
Entheon Biomedical is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N …
Entheon is powered by an unwavering commitment to significantly improve the odds of beating addiction for people who otherwise might now
Entheon Biomedical is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders.
Entheon is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming human trial, EBRX-101 is one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT in order to advance it as a therapeutic for addiction disorder.
In addition, Entheon is focusing on the identification, analysis and predictive use of genetics and EEG biomarkers to develop a treatment system that personalizes patient care through all stages of the treatment continuum.
For more information on Entheon Biomedical Corp. (CSE: ENBI, OTCQB: ENTBF) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
Harvest HPYE ETF Income Strategy for Volatile Markets
Harvest Premium Yield Enhanced ETF (HPYE) is built to help investors earn regular income and manage market swings by combining high-quality U.S. equities with an active options strategy using calls and puts.
Harvest HPYB ETF Income From Canadian Banks
Harvest Premium Yield Canadian Bank ETF (HPYB) is built to generate higher income from Canadian bank stocks by combining bank exposure with an active options strategy that sells calls and puts, producing more tax-efficient cash flow than dividends alone.
